Tango Therapeutics
TNGX
21.73
-0.98
-4.32%
Tango Therapeutics
US · TNGX
#2322 by market cap
Listed 1970
21.73
-0.98
-4.32%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:41
Recent news
-
Rating change
Guggenheim Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $35Market Newswire · 2026/8/12
-
Rating change
Jefferies Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $60Market Newswire · 2026/6/26
-
J.P. Morgan Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $47Market Newswire · 2026/11/10
-
Rating change
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $68Market Newswire · 2026/8/18
-
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $46Market Newswire · 2026/11/10
-
Rating change
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $68Market Newswire · 2026/10/29
-
Rating change
Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $55Market Newswire · 2026/10/24
-
Rating change
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT)TipRanks · 2026/8/12
-
Rating change
William Blair Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $42Market Newswire · 2026/10/16
-
Rating change
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $42Market Newswire · 2026/6/11
-
Guggenheim Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $35Market Newswire · 2026/11/10
-
Rating change
Jefferies Upgrades Tango Therapeutics(TNGX.US) to Buy Rating, Raises Target Price to $60Market Newswire · 2026/6/26
-
Rating change
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $66Market Newswire · 2026/6/11
-
Rating change
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $46Market Newswire · 2026/6/29
-
Rating change
J.P. Morgan Maintains Tango Therapeutics(TNGX.US) With Buy RatingMarket Newswire · 2026/10/13
-
Earnings Flash (TNGX) Tango Therapeutics Posts Q3 Loss $0.39 a Share, Vs. FactSet Est of $0.35 LossMT Newswires · 2026/11/9
-
A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $35 to $67Market Newswire · 2026/11/10
-
Rating change
Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/8/17
-
Rating change
Wedbush Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $39Market Newswire · 2026/8/12
-
Rating change
J.P. Morgan Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $46Market Newswire · 2026/7/15
-
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $46Market Newswire · 2026/10/12
-
Rating change
A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $32 to $66Market Newswire · 2026/6/10
-
Rating change
A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $35 to $42Market Newswire · 2026/6/9
-
Guggenheim Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $35Market Newswire · 2026/9/24
-
Rating change
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/5/22
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:41:45 · For reference only, not investment advice and not tailored to your situation.
Tango Therapeutics discussion 0 comments